BR9609006A - Peptìdeo, composição farmacêutica, e, processo para tratamento dse paciente. - Google Patents

Peptìdeo, composição farmacêutica, e, processo para tratamento dse paciente.

Info

Publication number
BR9609006A
BR9609006A BR9609006-5A BR9609006A BR9609006A BR 9609006 A BR9609006 A BR 9609006A BR 9609006 A BR9609006 A BR 9609006A BR 9609006 A BR9609006 A BR 9609006A
Authority
BR
Brazil
Prior art keywords
peptide
pharmaceutical composition
patient
treating
amino acid
Prior art date
Application number
BR9609006-5A
Other languages
English (en)
Inventor
Nicholas C Wrighton
William J Dower
Ray S Chang
Arun K Kashyap
Linda K Jolliffe
Dana Johnson
Linda Mulcahy
Original Assignee
Ortho Pharma Corp
Affymax Tech Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/484,631 external-priority patent/US5830851A/en
Priority claimed from US08/484,635 external-priority patent/US5773569A/en
Application filed by Ortho Pharma Corp, Affymax Tech Nv filed Critical Ortho Pharma Corp
Publication of BR9609006A publication Critical patent/BR9609006A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"PEPTìDEO, COMPOSIçãO FARMACêUTICA, E, PROCESSO PARA TRATAMENTO DE PACIENTE". Peptídeos com 10 a 40 ou mais resíduos de aminoácidos de comprimento e que tenham a seq³ência X~ 3~X 4~X~ 5~GPX~ 6~TWX~ 7~X~ 8~ (SEQ ID NO:) onde cada aminoácido é indicado pela abreviação padrão de uma letra; X~ 3~ é C; C~ 4~ é R, H, L, ou W; X~ 5~ é M, F ou Il X~ 6~ é independentemente selecionado a partir de qualquer um dos 20 L-aminoácidos geneticamente codificados; X~ 7~ é D, E, I, L ou V; e X~ 8~ é C, que se combinam com e ativam o receptor de eritropoietina (EPO-R), ou de outra forma, atuam como agonistas de EPO, e processos para seu uso.
BR9609006-5A 1995-06-07 1996-06-07 Peptìdeo, composição farmacêutica, e, processo para tratamento dse paciente. BR9609006A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/484,631 US5830851A (en) 1993-11-19 1995-06-07 Methods of administering peptides that bind to the erythropoietin receptor
US08/484,635 US5773569A (en) 1993-11-19 1995-06-07 Compounds and peptides that bind to the erythropoietin receptor
PCT/US1996/009810 WO1996040749A1 (en) 1995-06-07 1996-06-07 Compounds and peptides that bind to the erythropoietin receptor

Publications (1)

Publication Number Publication Date
BR9609006A true BR9609006A (pt) 1999-12-14

Family

ID=27048076

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9609006-5A BR9609006A (pt) 1995-06-07 1996-06-07 Peptìdeo, composição farmacêutica, e, processo para tratamento dse paciente.

Country Status (18)

Country Link
EP (2) EP1510524A3 (pt)
JP (3) JP4050314B2 (pt)
KR (1) KR100459984B1 (pt)
CN (1) CN1192748A (pt)
AT (1) ATE254138T1 (pt)
AU (1) AU712713B2 (pt)
BR (1) BR9609006A (pt)
CA (1) CA2223833C (pt)
CZ (1) CZ391097A3 (pt)
DE (1) DE69630708T2 (pt)
ES (1) ES2210374T3 (pt)
HU (1) HUP9901069A2 (pt)
IL (1) IL122417A0 (pt)
NO (1) NO318783B1 (pt)
NZ (1) NZ310804A (pt)
PL (1) PL185040B1 (pt)
TR (1) TR199701557T2 (pt)
WO (1) WO1996040749A1 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773569A (en) * 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5830851A (en) * 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
DE19904406A1 (de) * 1999-02-04 2000-08-10 Bayer Ag Substituierte Pyrazolcarbonsäuren
DE19904396A1 (de) * 1999-02-04 2000-08-10 Bayer Ag Substituierte Pyrazolbenzylamin-Derivate
US6703480B1 (en) 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
WO2004060406A2 (en) 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Polymeric reagents comprising a ketone or a related functional group
JP2007530440A (ja) 2003-05-12 2007-11-01 アフィーマックス・インコーポレイテッド 新規ポリ（エチレングリコール）修飾化合物およびその用途
NZ563042A (en) 2003-05-12 2008-09-26 Affymax Inc Novel spacer moiety for poly(ethylene glycol)-modified peptide-based compounds
US7528104B2 (en) * 2003-05-12 2009-05-05 Affymax, Inc. Peptides that bind to the erythropoietin receptor
WO2004101606A2 (en) 2003-05-12 2004-11-25 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
WO2005000360A2 (en) 2003-05-23 2005-01-06 Nektar Therapeutics Al, Corporation Peg derivatives having an amidocarbonate linkage
WO2005028539A2 (en) 2003-09-17 2005-03-31 Nektar Therapeutics Al, Corporation Multi-arm polymer prodrugs
PT1694363E (pt) 2003-12-16 2014-02-20 Nektar Therapeutics Composições monodispersas de naloxol peguilado
DK1725580T3 (da) * 2004-03-17 2009-03-23 Aplagen Gmbh Isosterisk transformation
US9085659B2 (en) 2004-05-03 2015-07-21 Nektar Therapeutics Polymer derivatives comprising an imide branching point
WO2005108463A2 (en) 2004-05-03 2005-11-17 Nektar Therapeutics Al, Corporation Branched polyethylen glycol derivates comprising an acetal or ketal branching point
EP1812461A2 (en) * 2004-11-10 2007-08-01 AplaGen GmbH Molecules which promote hematopoiesis
US7589063B2 (en) 2004-12-14 2009-09-15 Aplagen Gmbh Molecules which promote hematopoiesis
AU2005310189A1 (en) * 2004-11-11 2006-06-08 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
CN101198321A (zh) * 2005-04-26 2008-06-11 味之素株式会社 骨髓祖红细胞分化诱导剂
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
JP2008546732A (ja) * 2005-06-23 2008-12-25 アプラゲン ゲーエムベーハー 多価化合物
US8071554B2 (en) * 2005-08-05 2011-12-06 Araim Pharmaceuticals, Inc. Tissue protective peptides and uses thereof
MX2008011389A (es) * 2006-03-09 2009-01-26 Aplagen Gmbh Moleculas modificadas las cuales promueven hematopoyesis.
CN101528263B (zh) 2006-06-30 2013-01-23 Sku资产管理有限公司 用于癌症的先天性免疫方法的缀合物
US8106154B2 (en) 2007-01-31 2012-01-31 Affymax, Inc. Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules
EP2018835B1 (de) 2007-07-09 2014-03-05 Augustinus Bader Wirkstoff abgebendes Pflaster
CN101456911A (zh) * 2007-12-12 2009-06-17 江苏豪森药业股份有限公司 促红细胞生成素模拟肽衍生物及其可药用盐和其制备方法与用途
WO2009142679A2 (en) * 2008-03-26 2009-11-26 Orthologic Corp. Methods for treating acute myocardial infarction
US8575102B2 (en) 2008-08-01 2013-11-05 Nektar Therapeutics Conjugates having a releasable linkage
MX2011001583A (es) 2008-08-11 2011-04-04 Nektar Therapeutics Conjugados de alcanoato polimericos de multiples brazos.
EP2331139B1 (en) 2008-09-11 2019-04-17 Nektar Therapeutics Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
US20110166063A1 (en) 2008-09-19 2011-07-07 Nektar Therapeutics Polymer conjugates of therapeutic peptides
KR101647164B1 (ko) * 2008-09-26 2016-08-09 암브룩스, 인코포레이티드 변형된 동물 에리트로포이에틴 폴리펩티드 및 이의 용도
WO2010148365A2 (en) * 2009-06-19 2010-12-23 The Arizona Board Of Regents, A Body Corporate Of The State Of Arizona For And On Behalf Of Arizona State University Compound arrays for sample profiling
WO2011012306A2 (en) 2009-07-30 2011-02-03 Aplagen Gmbh Use of emps for antagonising epo-stimulatory effects on epo-responsive tumors while maintaining erythropoiesis
ES2632164T3 (es) 2010-07-06 2017-09-11 Augustinus Bader Aplicación tópica de eritropoyetina para uso en el tratamiento de lesiones de la córnea
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012166555A1 (en) 2011-05-27 2012-12-06 Nektar Therapeutics Water - soluble polymer - linked binding moiety and drug compounds
JPWO2013171810A1 (ja) 2012-05-14 2016-01-07 パナソニックＩｐマネジメント株式会社 耐熱性抗体提示ファージを得る方法
CN103450348B (zh) * 2012-05-29 2016-03-30 中国人民解放军军事医学科学院毒物药物研究所 一种促红细胞生成素模拟肽、其制备方法和用途
CN106608906A (zh) * 2015-10-22 2017-05-03 天津药物研究院有限公司 一种具有刺激红细胞生成功能的环形多肽的制备及其应用
CN106928338A (zh) * 2015-12-31 2017-07-07 杭州阿德莱诺泰制药技术有限公司 促红细胞生成素肽及衍生物和聚合物、制备方法和应用
GB201609083D0 (en) 2016-05-24 2016-07-06 Syntab Therapeutics Gmbh Synthetic compound
CN113166203A (zh) * 2018-09-14 2021-07-23 Epo医药株式会社 抗促红细胞生成素受体肽
US20220296521A1 (en) 2019-06-10 2022-09-22 Respira Therapeutics, Inc. Carrier-based formulations and related methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
WO1990008822A1 (en) * 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
DE3924746A1 (de) * 1989-07-26 1991-01-31 Behringwerke Ag Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers

Also Published As

Publication number Publication date
NO318783B1 (no) 2005-05-09
CN1192748A (zh) 1998-09-09
EP0886648B8 (en) 2004-03-03
ES2210374T3 (es) 2004-07-01
JP2007277264A (ja) 2007-10-25
EP0886648A4 (en) 2000-01-12
DE69630708T2 (de) 2004-08-05
ATE254138T1 (de) 2003-11-15
KR19990022656A (ko) 1999-03-25
PL323858A1 (en) 1998-04-27
NZ310804A (en) 1998-10-28
EP1510524A3 (en) 2006-06-07
NO975729L (no) 1998-02-05
AU6166796A (en) 1996-12-30
TR199701557T2 (xx) 2002-06-21
HUP9901069A2 (hu) 1999-07-28
EP1510524A2 (en) 2005-03-02
EP0886648A1 (en) 1998-12-30
DE69630708D1 (de) 2003-12-18
JP2009280616A (ja) 2009-12-03
AU712713B2 (en) 1999-11-11
CZ391097A3 (cs) 1998-07-15
JPH11507367A (ja) 1999-06-29
KR100459984B1 (ko) 2005-06-20
NO975729D0 (no) 1997-12-05
EP0886648B1 (en) 2003-11-12
CA2223833C (en) 2010-12-21
PL185040B1 (pl) 2003-02-28
CA2223833A1 (en) 1996-12-19
WO1996040749A1 (en) 1996-12-19
JP4050314B2 (ja) 2008-02-20
IL122417A0 (en) 1998-06-15

Similar Documents

Publication Publication Date Title
BR9609006A (pt) Peptìdeo, composição farmacêutica, e, processo para tratamento dse paciente.
Wilkinson Troponin C from rabbit slow skeletal and cardiac muscle is the product of a single gene
Butler et al. Proteins of the periodontium. Identification of collagens with the [alpha1 (I)] 2alpha2 and [alpha1 (III)] 3 structures in bovine periodontal ligament
AT408100B (de) Pth-analoga
Bugler et al. RNA binding fragments from nucleolin contain the ribonucleoprotein consensus sequence.
Wang et al. The nucleic acid binding activity of nucleolar protein B23. 1 resides in its carboxyl-terminal end.
Siegel Biosynthesis of collagen crosslinks: increased activity of purified lysyl oxidase with reconstituted collagen fibrils
Gibney et al. Divergence in primary structure between the molecular forms of acetylcholinesterase.
Seger et al. Structure and bioactivity of the amino-terminal fragment of pro-opiomelanocortin
BR9712348A (pt) molécula de polinucleotídeo isolada, vetor de expressão, célula cultivada em que foi introduzido um vetor de expressão, processo para produzir um polipeptídeo homólogo de fgf, polipeptídeo homólogo de fgf isolado,composição farmacêutica, anticorpo, processos para estimular ex vivo células progenitoras de miócitos, e, paraliberar um agente ou droga seletivamente para o tecido do coração.
EP0861894A4 (en) POLYPEPTIDE THAT SUPPRESSES DIFFERENTIATION
NO20065528L (no) Forbindelser som fremmer vevsvekst.
BR9810911A (pt) Composto, e, processo para tratar câncer em um mamìfero
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
Fukui et al. Identification of activins A, AB, and B and follistatin proteins in Xenopus embryos
BR9803960A (pt) Gene de desidrogenase de d-sorbitol.
BR9811592A (pt) Oxidase de citocinina
BR9607628A (pt) Mólecula proteinácea biologicamente isolada, molécula recombinante, fragmento de peptìdeo, molécula de ácido nucleico, composição farmacêutica, e, processos para preparar uma molécula recombinante e para induzir a proliferação astroglial em um mamìfero
KR930010177A (ko) 하이브리드 형질전환 성장인자
BR9811755A (pt) Peptìdeo, processo para o tratamento da obesidade em um animal, uso de um peptìdeo, e, composição farmacêutica
EP0228192A3 (en) Renin-inhibitory oligopeptides, their preparation and use
EP0203696A3 (en) Stabilized radiolabelled compounds
Lu et al. The primary structure of tubulin sequences of the carboxyl terminus and seven other cyanogen bromide peptides from the α-chain
DE3769910D1 (de) Verwendung von n, n'-bis-l-aminosaeure-l-cystinpeptiden in aminosaeure-praeparaten fuer orale und parenterale ernaehrung.
ES2080060T3 (es) Proteinas que tienen actividad de union a interferon-gamma.

Legal Events

Date Code Title Description
FD5 Application fees: dismissal - article 86 of industrial property law